-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Reinstates Overweight on Tarsus Pharmaceuticals, Announces $110 Price Target

Benzinga·09/16/2026 12:58:05
Barclays analyst Glen Santangelo reinstates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Overweight and announces $110 price target.